More than one hundred industry executives and experts provided insight into what to expect for the year ahead. Here’s what we’ve read so far… Technological Advances Today’s article explores the technological advances expected during 2023. Developments in data science and molecular biology drive expectations – for another year of breakthrough innovation in human therapeutics. However, […]
Optimum Strategic Communications sends our heartfelt congratulations to Jane Osbourn OBE, the co-founder and chief scientific officer of Alchemab, who was presented with a Lifetime Achievement Award by the BioIndustry Association last night, in recognition of her achievements as a leading figure in UK life science. Before founding Alchemab, Jane served as vice president at […]
… And just like that it’s ANOTHER new year! If you are still gathering your thoughts on how best to maximise your time in 2023, allow us to flag some of the most impactful and innovative conferences in Life Sciences. The Optimum team really enjoyed being back in person for the majority of the conferences […]
In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023. According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery. Check out the Evaluate team’s thoughts on the […]
It’s nearly the end of 2022! It was an exciting year for Optimum’s clients which demonstrated the resilience and creativity that has made the life sciences industry so successful. We have outlined below a small fraction of the activity that has kept us busy this year: Deal, deals, deals As usual, 2022 was a year […]
